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Abstract
Despite widespread availability of a large body of evidence in the area of hypertension, the
translation of that evidence into viable recommendations aimed at improving the quality of health
care is very difficult, sometimes to the point of questionable acceptability and overall credibility of
the guidelines advocating those recommendations.
The scientific community world-wide and especially professionals interested in the topic of
hypertension are witnessing currently an unprecedented debate over the issue of appropriateness
of using different drugs/drug classes for the treatment of hypertension. An endless supply of recent
and less recent "drug-news", some in support of, others against the current guidelines, justifying the
use of selected types of drug treatment or criticising other, are coming out in the scientific
literature on an almost weekly basis. The latest of such debate (at the time of writing this paper)
pertains the safety profile of ARBs vs ACE inhibitors.
To great extent, the factual situation has been fuelled by the new hypertension guidelines (different
for USA, Europe, New Zeeland and UK) through, apparently small inconsistencies and conflicting
messages, that might have generated substantial and perpetuating confusion among both
prescribing physicians and their patients, regardless of their country of origin.
The overwhelming message conveyed by most guidelines and opinion leaders is the widespread use
of diuretics as first-line agents in all patients with blood pressure above a certain cut-off level and
the increasingly aggressive approach towards diagnosis and treatment of hypertension. This,
apparently well-justified, logical and easily comprehensible message is unfortunately miss-obeyed by
most physicians, on both parts of the Atlantic.
Amazingly, the message assumes a universal simplicity of both diagnosis and treatment of
hypertension, while ignoring several hypertension-specific variables, commonly known to have high
level of complexity, such as:
- accuracy of recorded blood pressure and the great inter-observer variability,
- diversity in the competency and training of diagnosing physician,
- individual patient/disease profile with highly subjective preferences,
- difficulty in reaching consensus among opinion leaders,
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- pharmaceutical industry's influence, and, nonetheless,
- the large variability in the efficacy and safety of the antihypertensive drugs.
The present 2-series article attempts to identify and review possible causes that might have, at least
in part, generated the current healthcare anachronism (I); to highlight the current trend to account
for the uncertainties related to the fixed blood pressure cut-off point and the possible solutions to
improve accuracy of diagnosis and treatment of hypertension (II).
Introduction and magnitude of the background 
problem
Recent changes in definition and classification of blood
pressure levels make hypertension, by far, the most com-
monly diagnosed condition in primary and secondary
healthcare systems and projects the entity on the first
place in terms of work load and prescribing cost.
"People with normal blood pressure by their 50 years of
age are considered to run a 90% life-time risk for develop-
ing hypertension later during their lives"[1].
This statement puts in perspective the epidemic nature of
hypertension and the growing concern of all societies in
dealing with this outstanding public health problem, in
developed as well as in developing countries.
There is little doubt that the American [1], the European
[2], the British [3] and the WHO [4] guidelines on hyper-
tension have the same, common goal of improving the
quality of health care by changing the behaviour of pro-
viders and by improving the effectiveness of hypertension
management in daily practice. Overall, current guidelines
have become larger documents, apparently more compre-
hensive and increasingly evidence-based. Despite these
obvious improvements, guidelines are hardly, if at all,
implemented in clinical practice.
The demographic and socio-economic profile of 
hypertension
The National Health and Nutritional Health Survey
(NHANES) [5] data from 1999 to 2000 reported a 3.7-per-
centage point increase in the hypertension prevalence rate
with more than 42% of hypertensives being not at all
treated, almost 30% of them being unaware of their ill-
ness and 69% not being controlled. Reported control rates
are even lower in European countries, only 8% on average
[6]. Approximately 75 million adults (34% of the whole
population) have blood pressure above 140/90 mmHg in
five European countries (UK, Germany, France, Italy and
Sweden) [7].
These disappointing figures are in sharp contradiction
with the hypertension-related successes over several years
before the survey.
Even worse, the recently published results of an epidemi-
ologic inquiry to assess the hypertension burden and
overall prevalence for the same period (1999 to 2000) in
US [8] showed that, in fact, the total hypertension preva-
lence rate reached 31.3% amounting to at least 65 million
adults in US having hypertension. This is an almost 30%
increase of the frequently quoted figure for the magnitude
of hypertension in terms of prevalence based on the
NHANES III estimation of "50 million adults" with hyper-
tension in the US [8].
Besides, the newly minted prehypertension category in the
JNC VII-hypertension classification [1], introduced on
fully justifiable reasons, ads further to the hypertension-
related public health burden. In a sample of 3,488 per-
sons of the same NHANES III survey, among people aged
20 years or older, 29% were hypertensive, 31% were pre-
hypertensive and 39% were normotensive, with consider-
able greater percent of prehypertensives in men than in
women (39.0% versus 23.1%) and in blacks as compared
with whites (37.4% versus 32.2%) [9,10]. About 59 mil-
lion American adults (29%) fall into the prehypertension
category.
These data suggest that more than 60% of the American
adults are either hypertensive or prehypertensive. Notice-
ably, the prehypertesives were 1.65 times more likely to
have at least one other major risk factor (total cholesterol
or overweight) than were those with normotension. Fur-
thermore, in a simulation applied to a sample of 10,000
adults aged 25–74 years, the considerably high prevalence
of prehypertensives in the higher age groups (two-thirds
among people aged 45–65 years and 80% of those aged
65–74 years) indicated that prehypertension might
account for 3.4% of hospitalisation, 6.5% of nursing
home stays, and 9.1% of deaths [11].
These health-related alarming trends are ascribed to the
increasing prevalence of obesity in the general population
as well as to the aging, respectively, to the growing seg-
ment of elderly in the general population.
Interestingly, the two latter demographic aspects are
results of increased life expectancy [12-14] in the context
of "healthier lifestyles and/or better control ratesCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:6 http://cvm.controlled-trials.com/content/6/1/6
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associated with hypertension-related public health effec-
tiveness and medical care quality improvement", a mix of
factors termed: "higher control-survival-burden paradox"
[5].
Paradoxically indeed, improved hypertension-focused
medical care has simultaneously increased the burden on
public health systems worldwide! Estimating further this
burden in the American-context, the 23 million hyperten-
sive adults estimated to take antihypertensive medication
generate costs of about $15bn (€12bn), i.e., 10% of the
country's total spending on drugs [15].
Estimated total direct and indirect cost of hypertension for
2005, as a result of its increased prevalence, is around $60
billion while, the total cost for cardiovascular disease and
stroke for 2005 is estimated to be $393.5 billion [16].
According to the same source [16], hypertension was
listed as a primary or contributing cause of death in about
261,000 of about 2.4 million US deaths in 2002, repre-
senting a 57% increase in death from hypertension over
the past few decades.
The projected addition of some 30 million individuals
aged 60 years or older in the next 20 years [17] as well as
the widespread consensus and willingness to increase the
number of those effectively treated for their hypertension,
emphasizes the potential for escalating costs that may
blow out of proportion and the seriousness of the
hypertension-epidemic.
In this context, it is obvious that there is a tremendous
need for wide-scope, systematically driven cost-effective
prevention and treatment, and for more effective control
strategies at all levels of healthcare systems.
However, a holistic, comprehensive strategic approach
must not only target hypertension as pathological entity,
but must take into account the wider environment in
which hypertension is a major risk factor for cardiovascu-
lar disease and its interplay in the constellation of other,
well-known modifiable risk factors such as: tobacco use,
hypercholesterolemia, overweight/obesity, physical inac-
tivity, diet and, to great extent and more often, associated
diabetes mellitus [18-20].
Diagnosing hypertension – sources of errors in blood 
pressure measurement
Blood pressure measurement is by far, the most com-
monly performed screening tests in medical practice and,
because the act of measuring blood pressure is perceived
as simple and straightforward it has also become the most
commonly used "in house" self-employed test.
For only 20 years ago, the task of people willing to moni-
tor their blood pressure was considerably easier, at least as
far as the reference value for normal/abnormal blood
pressure was concerned. It could simply be derived by eve-
ryone just by adding his/her age to 100 and consider the
resultant value as cut-off point for threshold to abnormal-
ity. Advice from physician was eventually sought as to
whether drug treatment was appropriate or not.
However, gradually, the age-standardized BP became
obsolete and things started to be more complicated, not
only for lay people interested in monitoring themselves
but also for physicians and nurses. Accuracy of measure-
ment itself has become an issue while adjustment to ever
changing "target cut-off points" (reference ranges) is
widely required.
So, the apparent user-friendliness of the blood pressure
measurement techniques is made more questionable by
the evolving changes in the definition, classification, diag-
nosis and management recommendations in the area of
hypertension. As a consequence, both professionals as
well a lay people wishing to continue to measure blood
pressure are currently supposed to comply with guidelines
for blood pressure measurement [21](see Additional file
1), if they are to believe what they are measuring.
Observer bias
Despite the clear guidelines on blood pressure measure-
ment technique, there seems to be large inter-observer
variations, both among nursing staff and physicians as
well as between the two groups. A questionnaire meant to
focus this issue, encompassing 28 senior nurses and 55
health professionals from 28 different clinics in UK, high-
lighted considerable such variation leading consequently
to inappropriate action [22-24]. A similar questionnaire
carried out in Sao Paulo State on 105 professionals as to
their compliance with the blood pressure measurement
recommendations by Perloff et al. [21], showed that nurs-
ing staff abided by 40% of the recommended procedures
while medicine teachers, physicians and residents abided
by approximately 70% [25].
Conventionally, differences of 5 mmHg are considered
clinically significant although, results derived from more
recent trials such as VALUE (26) and ALLHAT [27] indi-
cated that blood pressure differences of 2 to 4 mmHg
might be clinically important. In this context, errors in
blood pressure measurement in excess of 15 mmHg or
more, as reported by Campbell et al. [28], are obviously
leading to misclassification of hypertensive patients and
inappropriate treatment.
What is more worrying, while in the same time at least
partially explaining why such huge discrepancies mayCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:6 http://cvm.controlled-trials.com/content/6/1/6
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occur in practice, is the fact that gaps in the basic theoretic
and practical knowledge seem to be common among
interns and first-year family practice residents, supposed
to have just acquired the skills for accurate blood pressure
measurement [29]. An interesting observational study in
this respect, carried out at the Westminster Medical School
in London, showed that 33% out of 80 doctors in training
grades/junior hospital doctors, acknowledged no formal
education on how to measure blood pressure, a finding
confirmed further by the poor accuracy in blood pressure
measurement displayed by one third of the study group
[30].
The human error impact is further compounded by varia-
bles such as: cuff selection and application, incorrect cuff
positioning and rapid cuff deflation rate [20,31], inade-
quate rest period [31], digit bias and lack of repeated
measurements (see Additional file 2).
Faulty equipment
Adding considerably to the degree of "human error" in the
area of blood pressure measurement is the universally
poor state of the measurement devices available, their
inaccuracy and the unreliability of the measurement
results generated.
A study, aimed to assess the accuracy of calibration and
evaluation of physical condition of 524 sphygmomanom-
eters (mercury and aneroid) used in hospital settings or
private medical offices, showed that 44% of the aneroid
sphygmomanometers used in hospital settings and 61%
of those used in private medical practices were found inac-
curate. The magnitude of inaccuracy ranged from 4–6
mmHg in 32% to more than 13 mmHg in 7% of the tested
devices. It was concluded that the mercury and aneroid
sphygmomanometers showed inaccuracies of 21% versus
58% and unreliability of 64% versus 70%, respectively
[32].
Another study, aimed at the assessment of maintenance
and calibration of sphygmomanometers used in 231 Eng-
lish general practices, showed that 9.2% of the 1,462
sphygmomanometers tested gave readings that were more
that 5 mmHg inaccurate and that one in 54 practices had
an arrangement for maintenance and calibration of the
measurement devices [33].
A British study carried out in 18 practices and 67 GP
offices showed digit bias in systolic and diastolic readings
to the nearest 10 mmHg [34].
Lack of standardized blood pressure measurement devices
Because of its accuracy and reliability, the mercury sphyg-
momanometer is generally regarded as the gold standard
against which all other devices for blood pressure meas-
urement should be compared [35]. Unfortunately, due to
the widespread concern that the mercury contaminates
the environment, the mercury sphygmomanometers are
about to be replaced largely with alternative equipment
[36].
In contrast to the mercury sphygmomanometer that is
least dependent on calibration and maintenance [37], the
aneroid devices need calibration against a known stand-
ard (mercury manometer or non-mercury pressure
meters) at six months interval. Failed calibration test
implies the need to return the device to the manufacturer.
Lack of calibration and maintenance of the aneroid sphyg-
momanometers, as reported by numerous studies carried
out in different parts of the world, makes them highly
doubtful for routine use in medical practice, unless
aggressive programs of maintenance and calibration will
be implemented in timely manner in order to overcome
the problems associated with inaccurate measurement of
blood pressure [38].
A second type of alternative blood pressure measurement
device is the electronic automated manometer. Such a
device assesses the oscillations of pressure in the cuff dur-
ing deflation. The point of maximal oscillation corre-
sponds to the mean intra-arterial pressure. The systolic
and diastolic pressures are computed on the basis of an
algorithm, commonly known to be patent protected. This
means, in turn, that algorithms used by different manu-
facturers vary from device to device [39]. Besides, these
devices display a particular vulnerability in certain clinical
circumstances, such as patients with arrhythmias and with
stiff arteries. Likewise, they are prone to error because of
the dependence of the cuff deflation rate to the heart rate.
If the deflation is too rapid or the heart rate is too slow
(e.g., in patients treated with beta-blockers), inaccurate
blood pressure measurement is likely to occur [40].
Allegedly, most of these blood pressure measurement
devices are subject to validation according to internation-
ally accepted protocols of the Association for the Advance-
ment of Medical Administration (AAMI) or the British
Hypertension Society (BHS). The latest validation proto-
col has been issued by the European Society of Hyperten-
sion, slightly modified as compared to the two protocols
mentioned above [41].
Disappointingly, however, commercially available auto-
mated devices that have passed validating study protocols
still display significant inaccuracies in blood pressure
measurement. Gerin et al. showed that blood pressure
measurements with such devices were inaccurate by at
least 5 mmHg in 20 to 38% of the individuals tested [42].
Schwartz et al. state that when using blood pressureCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:6 http://cvm.controlled-trials.com/content/6/1/6
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monitors that meet the AAMI and BHS validation criteria,
more than 50% of the persons tested may have average
measurements that are in error by more than 5 mmHg
[43].
Even worse is the fact that many of the most commonly
used blood pressure monitors in clinical practice, in US
[44], have never passed an AAIM certification and do not
even need to do so as there are no regulatory requirements
in this respect.
Blood pressure variability and its assessment by 
ABPM
Assuming that successful precaution measures would be
taken with regard to all the above mentioned sources of
errors, the office blood pressure measurement would still
not be an accurate reflection of an individual subject's true
blood pressure and of its impact on the on that subject's
long term outcome.
Apart from the imperfection of the Korotkoff technique as
compared with the intra-arterial blood pressure measure-
ments [45], just adding to the aforementioned potential
sources of error, the great diurnal variability inherent in
the blood pressure behaviour (see Additional file 3) is per-
haps the major issue that makes office blood pressure
measurement a screening test at best, and unqualifies it as
a diagnostic test.
Ambulatory blood pressure measurement (ABPM), now
in use since more than 25 years, has been gaining wide
acceptance during the past few years. Current guidelines
recommend use of the method in selected cases (see Addi-
tional file 4) [46-49], however, in the light of more recent
data [50,51,63], ABPM is about to emerge as the method
of choice for ensuring an accurate "first time" hyperten-
sion diagnosis, for refining cardiovascular risk stratifica-
tion in most of the newly-diagnosed hypertensives and for
the ability to confidently start or postpone pharmacologic
treatment in a particular individual. Furthermore, ABPM
allows for assessment of prognosis and therapeutic
guidance.
A 24-hour ambulatory blood pressure curve (see Fig. 1)
fully illustrates the large, diurnal intraindividual variabil-
ity of the blood pressure and suggests that great differ-
ences may be encountered when comparing such data
with the data collected from single or a few readings in the
physician's office.
The great uncertainty that lies in casual blood pressure
measurements, reflecting the biologic variations of this
parameter, has been emphasized through Bayesian analy-
sis [52] and a prospective trial of home blood pressure
monitoring [53]. These studies demonstrated that 11
respectively 15 blood pressure readings generated mean
values that accounted for 80% of the variation in any one
single measure. Likewise, blood pressure readings per-
formed on different days display large variability as
reflected by mean standard deviations as high as 12/8
mmHg [54]. The regression to mean phenomenon is
known to further dilute blood pressure measurement
results.
The total range of variation observed for 24-hour mean in
healthy pregnant women is even larger; 28 and 26 mmHg
for SBP and DBP, respectively. This range of blood pres-
sure variability is approximately three times larger when
computed on the basis of individual blood pressure meas-
urements instead of the 24-hour mean [55].
It has been estimated that use of a single blood pressure
measurement to assist in diagnostic decision making
would overdiagnose hypertension in 20–30% of cases
and miss a third of those who truly have the disease
[56,57].
The white coat effect, defined as an office blood pressure
exceeding mean daytime ambulatory pressure by at least
20 mmHg systolic and/or 10 mmHg diastolic has been
found in as many as 73% of treated hypertensive subjects.
It may occur more frequently in women than in men [58]
and it is virtually impossible to be diagnosed on clinical
examination alone [59].
White-coat hypertension (defined as high blood pressure
only in the medical care environment) is reported in as
many as 20 to 35% of patients in whom hypertension is
diagnosed [60,61] and in nearly 30% of pregnant women
[62]. ABPM in elderly of Syst-Eur trial showed that blood
pressure was on average 22 mmHg higher on conven-
tional than on daytime ambulatory measurement [63].
Likewise, the ABPM in the same trial revealed that older
patients have a general propensity toward hypotensive
states of different aetiologies reflecting considerable diur-
nal blood pressure variability, with periods of hypoten-
sion alternating with hypertension. This translates into
the well-known elderly's greater susceptibility to adverse
drug events and calls for accurate diagnosis and appropri-
ately tailored treatment.
Newer insights in this area, further emphasizing the tre-
mendous complexity of hypertension per se, comes from a
study comparing the long-term, office blood pressure
measurements with 24-hour ambulatory blood pressure
measurement in treated hypertensive patients [64].
The study by Clement et al. [64] showed that when office
and ambulatory blood pressure are compared as to their
impact on the long-term prognosis, ambulatory bloodCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:6 http://cvm.controlled-trials.com/content/6/1/6
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pressure predicts prognosis significantly better, even after
adjustment for any associated risk factors.
Among several valuable findings of this study, the most
notable is that patients whose mean 24-hour systolic pres-
sure was 135 mmHg or higher, when they were receiving
treatment, were nearly twice as likely to have a cardiovas-
cular event as patients with a mean 24-hour systolic pres-
sure of less than 135 mmHg, regardless of their office
blood pressure values.
The use of 24-hour ambulatory blood pressure measure-
ment seems to be a sine qua non condition for accurate
diagnosis in cases with hypertension recently termed
reversed  or  masked  hypertension [65,66], in which the
office pressure used to be lower than the ambulatory pres-
sure. It was estimated that only in US might be as many as
10 million subjects having this type of hypertension [43].
The new entity requires special attention to be given in
two different clinical scenarios:
1). Patients with high office pressure but with low ambu-
latory pressure (no more likely than normotensive per-
sons to have a cardiovascular event); intensive treatment
of these patients, exclusively on the basis of office blood
pressure measurement and/or their labelling as having
"resistant hypertension" (in absence of associated risk fac-
tors or established organ damage), is likely to be deleteri-
ous and, it may even lead to adverse drug events;
2). Patients with low office blood pressure but high ambu-
latory blood pressure (who are in the opposite extreme of
the hypertension spectrum); apparently, these patients are
"well controlled", however, in need of intensified treat-
ment as they seem to be running a worse long-term
prognosis.
Consequences of errors in blood pressure 
measurement
The multiple sources of errors that may be encountered in
the office blood pressure measurement emphasize the
Blood pressure variability in healthy individual recorded by 24-hour ABPM Figure 1
Blood pressure variability in healthy individual recorded by 24-hour ABPM.
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great degree of non-accurate, misleading results generated
by such assessments in daily clinical practice. Two
examples bellow highlight the consequences of only min-
imal biased assessments (e.g., ± 5 mmHg).
An overestimating systematic error of 5 mmHg would
misclassify some 27 million people as being hypertensive
rather than having normal-high blood pressure, i.e., pre-
hypertension [67]. The individual and societal conse-
quences of initiating drug treatment in this segment of the
population might be huge and, eventually translate into a
real public health burden. Namely, patients with a low
absolute risk may be exposed to the potential side effects
of a treatment for little or no therapeutic benefit.
Further, a systematic error of underestimating true blood
pressure by 5 mmHg would mean that 21 million people
would go untreated as their real hypertension would be
labelled as normal-high blood pressure [67]. In this sce-
nario, patients with high absolute risk who are misclassi-
fied as having controlled hypertension will have a higher
risk of cardiovascular event than necessary.
Both these scenarios may occur with rather high probabil-
ity in clinical practice given the current, widespread model
of healthcare based on a dichotomous paradigm of "yes/
no" decision making as to establishing an initial diagno-
sis, as to the need to investigate or not investigate or, to
treat or not to treat, currently arbitrarily fixed for hyper-
tension at 140/90 mmHg.
Amazingly, the scientific community seems to accept the
particular outlook reflected by this dichotomous reason-
ing despite widespread awareness that the risk associated
with increasing blood pressure is graded and continuous.
It begins as low as at 115/75 mmHg [1] and increases
gradually without, however, a particular threshold being
known on the BP curve that might discriminate between
risk/no risk circumstances [68].
The lack of such a threshold combined with the informa-
tion derived from a multitude of clinical trials, convinc-
ingly demonstrating the benefits of treatment across all
levels of blood pressure in Western populations (not only
in hypertension) [69-71], have generated "the lower the
blood pressure, the better" – treatment philosophy, applica-
ble to the general population and advocated as such by
the majority of current guidelines.
The <140/90 mmHg cut-off point (respectively <130/80
mmHg for those with compelling indications) have been
chosen as treatment goal/target  for pharmacologically
treated hypertensives. These targets are supposed to be
pursued aggressively with even three or four drugs if
needed, in order to achieve "optimal" or "normal" BP in
young, middle-aged, or diabetic subjects (below 130/80
mmHg), and at least "high-normal" BP in elderly patients
(i.e., <140/90 mmHg) [72,73].
Unfortunately, current evidence indicates that most
patients fail to achieve systolic blood pressure below 140
mmHg [74-76]. According to a survey of hypertension in
10 countries worldwide, the proportion of patients
achieving a blood pressure target below 140/90 mmHg
ranged from a maximum of 27% in the USA to a mini-
mum of less than 3% in Zaire [77]. In clinical trials focus-
ing hypertension treatment the control rate is around 6%
[78].
Mancia and Grassi [79] pointed out that even in the case
of ideal scenario whereby "patient compliance and physi-
cian's expertise were ensured, attaining systolic blood
pressure control would neither frequently nor easily be
obtained".
Additionally, common sense suggests that there may be a
level at which the benefits of treatment are outweighed by
its side effects [80]. Likewise, it is obvious that the abso-
lute benefits gained differ substantially between elderly
and middle aged people and those with or without pre-
existing cardiovascular disease [81,82]. Appropriate
assessment of these variables is a matter of judgement of
the treating physician, based not on occasional blood
pressure measurements but rather, on complex clinical
decision making employed on a case-to-case basis [83-
88].
The aforementioned major problems with accurately
measuring blood pressure in day-to-day clinical practice
for the purpose of diagnosis and treatment of hyperten-
sion, highlight the magnitude of the uncertainty range
around the current blood pressure cut-off point (140/90
mmHg), consisting of huge number of people being mis-
diagnosed of having or not having hypertension.
Failure in both directions are regrettable but, in the con-
text of currently increasing aggressive approach to hyper-
tension mandated by most guidelines, overdiagnosis
exposes people unnecessarily to considerable risk for
adverse drug reactions (ADR).
Poor treatment compliance rates – often a 
reflection of overdiagnosis?
Patients' low compliance rate with the prescribed medica-
tion is a widely acknowledged problem in hypertension
treatment. Up to 50% of the patients quit the treatment
they were given within the first year [89-92]. Adverse
events with antihypertensive treatment are to a large
extent dose related. More than 75% of these ADRs occur
as such, at initiation of antihypertensive treatmentCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:6 http://cvm.controlled-trials.com/content/6/1/6
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[93,94]. In the commonly asymptomatic patients with
recent diagnosed hypertension, even adverse events of
trivial degree of intensity (mild headache, dizziness, etc.)
can be perceived as interfering with their normal life. This
reasoning has shaped treatment strategies during many
years toward the lowest effective dose (of whatever agent
had been used) at initiation of therapy, with the aim to
maximize the likelihood of successful early treatment and
improve the long-term compliance rate.
The task of the prescribing physician when attempting to
stick to the lowest effective dose principle is, however not
easy, as the labeling information at hand is often not
enough informative for confident decision making. This is
the case even when the doctors carefully take into account
the known individual variations in drug response due to
differences in age, weight, sex, ethnic background, state of
health, concomitant medication use, and genetic poly-
morphism in drug metabolism.
The all too high dosage of a particular drug at launch
seems to be inherent in the current drug development par-
adigm. Namely, high doses are selected during the early
clinical trials phases with the purpose of assessing the
agent's efficacy and less so its safety profile. Maximizing
efficacy by preferential selection of higher doses may,
obviously, be deleterious from safety point of view, partic-
ularly when such doses selected in early trials are used to
prove efficacy in later phase trials and eventually are
brought to the market once the drug is granted marketing
authorization. Several studies have highlighted deviations
in the post-licensing dose administration levels [95,96].
One study reported 115 instances of changes to the
defined daily dose (DDD) between 1982 and 2000. Of
these, about 60% were reductions relative to the initially
designated DDD. Of some reason, cardiovascular drugs
had the most DDD changes. In a similar study of changes
to labeling instructions after licensing by the FDA, 79% of
drugs underwent a reduction in drug dosage. Another
study reported a 69% decrease in the length of time after
marketing for the dosage change to occur [97]. The poor
dosage selection predisposes to adverse drug events and
consequent poor patient compliance.
The problem above is further compounded by the initial
drug dosage guidance available for physicians in US [98]
– the JNC guidelines and the Physicians' Desk Reference
(PDR). The latter seems to be the preferred source of ref-
erence for some 90% of American physicians [99] while
being used extensively also by consumers. A comparison
of the two sources (the JNC VI versus the PDR editions of
1999 and 2000) has revealed large dose disparities in 23
out of 34 drugs (68%) in five frequently prescribed anti-
hypertensives: ACEs, ARBs, BB, CCBs and diuretics. The
PDR initial doses were at least 100% higher than the JNC
VI doses except for chlorthalidone and a brand of meto-
prolol succinate. Furthermore, the PDR recommended
use of lower initial doses in elderly in only 8 (18%) of 45
different drugs. This is, certainly, a real problem as hyper-
tension is mostly prevalent among people above 60 years
of age, known to have physiologically decreased hepatic
and renal function and in whom clustering of multiple
risk factors and/or associated morbidities require daily
intake of several drugs. This constellation of factors makes
the elderly vulnerable to first-dose reactions such as hypo-
tension, dizziness, syncope, headaches, etc. Commonly,
these ADR are dose-related [100,101] and are the leading
cause of older patients discontinuing antihypertensive
therapy (102).
The well-intended use by many physicians of a "half-
dose" of a particular drug at initiation of treatment is
hampered by the impossibility of dividing capsules,
coated tablets and drugs with irregular format.
The "start low, go slow" principle, promoted constantly
during the past decades as a stepwise approach to treating
patients with hypertension, allows patients time to adjust
psychologically to the fact that they have hypertension. A
meta-analysis of 354 trials involving 56,000 participants
showed that blood pressure reductions produced by the
major classes of drugs at standard dose are similar, and
that half the standard dose reduces efficacy by only 20%
while more than halving side-effects [103-105].
Given the current prehypertension category, most "new
hypertensive" patients are counselled as to lifestyle
changes that either may fail or simply are not enough to
prevent  passing  the threshold to "real" hypertension
(>140/90 mmHg). The distress about having hyperten-
sion and possibly requiring life-long drug therapy may
lead to development of anxiety symptoms that may be
mistaken for ADR, which may lead to skipping doses or
quitting treatment.
Worse than that is the case of those patients who, through
the nature of their hypertension (e.g., white coat hyper-
tension with blood pressure in excess of 20/10 mmHg
above the cut-off point), are candidates for combination
treatment from the start. Indeed, for these patients, or
those whose blood pressure levels increase to these levels,
the current guidelines recommend that consideration
should be given to initiating (first-line) therapy with two
drugs, either as separate prescriptions or in fixed low-dose
combination. The main logic of these recommendations
is simplicity of use of such combinations and their poten-
tial to considerably improve the blood pressure response
rate while minimizing the incidence of adverse effects.Current Controlled Trials in Cardiovascular Medicine 2005, 6:6 http://cvm.controlled-trials.com/content/6/1/6
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This might be a best evidence approach in patients with
sustained hypertension diagnosed by ABPM but, it might be
a high-risk approach in cases with white coat hypertension,
not recognized by conventional office blood pressure
measurement.
Physicians' non-compliance with treatment 
guidelines
Proper diagnosis of hypertension is of paramount impor-
tance for successful implementation in the clinical prac-
tice of current treatment guidelines. Consequently, failure
to do so by the prescribing physician community suggests
that there might be difficulties with accurately diagnosing
hypertension, a fact, ultimately resulting in poor control
of hypertension.
As control of hypertension, defined as BP < 140/90 mm
Hg had been conferred status of quality indicator in the
Health Employer Data Information Set by the National
Committee for Quality Assurance in US [106], the poten-
tial reasons for any setback regarding this indicator are
exposed to careful research. It should be emphasized,
however, that the choice of this particular blood pressure
threshold is neither evidence-based nor universally
accepted.
Fourteen out of 27 national hypertension societies repre-
sented at the 17th  world conference of Hypertension
League Council held in Montreal in 1997 adopted the
140/90 mmHg cut-off point for hypertension diagnosis
while the remaining 13 societies stayed with 160/95
mmHg [107].
Not surprisingly, a questionnaire survey among primary
care physicians in US indicated that a significant propor-
tion of them were reluctant to seek treatment goal below
140/90 mmHg while, in the same time, being pretty toler-
ant with mildly elevated SBP in older patients. These find-
ings led the authors of the article [108] to make the
statement that "physician behavior makes a significant
contribution to the poor rates of hypertension control".
The situation is very similar in UK where an editorial by
Campbell entitled: "Patients decide how low they go, not
targets" [109], generated a wave of rapid responses reflect-
ing the general discontent with current guidelines on
hypertension [110].
Another issue of discontent among practicing physicians
is the way results of clinical trials are presented, a fact that
seems to impact the prescribing propensity of physicians
and the patients' willingness to accept treatment [111].
The apparently small range between the two thresholds
under debate (140/90 – 160/95 mmHg), encompasses
the great majority of individuals with hypertension in
whom most of the hypertension-related morbidity and
mortality is recorded [112,113]. Overlapping this range,
as a matter of fact, is the widespread uncertainty of the
practicing physicians as to how confidently to diagnose
the cases within this range, whether to initiate drug treat-
ment in them or not and, if yes, whether the benefit of
treatment will outweigh its potential risks.
Given that most of older hypertensive patients in general
practices have a clustering of risk factors [3], there is high
probability that in many cases a careful treatment
approach by the physician will need to take in considera-
tion the combined use of aspirin, a lipid lowering drug,
several antihypertensive agents and, in may cases, an anti-
diabetic agent as well. The high probability of this sce-
nario is generated by the NCEP III guidelines [114] that
lowered the eligibility requirements for using statin drugs
through moving the LDL-C threshold from = 4.1 mmol/L
to = 3.3 mmol/L. This change translated into some 36 mil-
lion people being in need for treatment, as compared with
15 million, before (a 140% increase) [115]. In addition to
this, the results of ASCOT-LLT [116] and the ALLHAT-LLT
[117] trials have expanded the relevance of lipid lowering
treatment to the majority of hypertensive patients.
Obviously, it is difficult to find an all-fit formula for all
these uncertainties; however, an emerging trend is to
incorporate into the treatment management decision
making the values and preferences of patients, clinicians
and the general public [118-121]. This is certainly a proc-
ess that is going on at the level of physician-patient rela-
tionship, unfortunately not always as transparent and well
documented as it should be. The consequence is that the
patient's choice [86-88] of, eventually, not be willing to
accept treatment is not recorded as such, with the physi-
cian getting the blame of leaving the patient untreated,
alternatively, insufficiently treated.
Philipps et al. [122] emphasized this problem as follows:
"Despite advances......, health care providers often do not
initiate or intensify therapy appropriately during visits of
patients with these problems. We define such behavior
clinical inertia – recognition of the problem but failure to
act on it".
"........achieving standard-of-care goals in only limited
numbers of treated patients must be attributed either to
therapeutic ineffectiveness or to clinical inertia. The
attainment of treatment targets in clinical trials shows the
effectiveness of present therapies for hypertension, ele-
vated LDL cholesterol levels, and diabetes – leaving clini-
cal inertia as the presumptive basis for treatment failure in
many patients with these disorders".Current Controlled Trials in Cardiovascular Medicine 2005, 6:6 http://cvm.controlled-trials.com/content/6/1/6
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The content of the first quote seems to ignore most of the
sensitive aspects that normally occur in the patient-physi-
cian relationship and in the mutual decision making proc-
ess of the two parts involved. Likewise, the second quote
assumes generalization of the mean global estimates of
clinical trials to the particular individual as a universal
task to be fulfilled by all practicing physicians.
Indeed, epidemiologic data indicate that the long-term
average BP is the best predictor for risk [123], however,
short-term measurements of office BP, especially when
they are near cut-off points for normal, all too often result
in false-positive diagnosis of hypertension [124].
But, "physician behavior" and failure of clinicians to
monitor blood pressure aggressively and institute phar-
macotherapy when indicated were invoked as causes for
poor control of hypertension already by the NHANES III,
in 1997 [125]. From that gentle form of being reminded
of their failures, practicing physicians have got to acquaint
themselves gradually with the thought that they really
deserved being blamed for "clinical inertia".
Most recently they could find out that they might be about
to loose entirely what was left of their credibility in terms
of diagnosing and treating hypertension.
In an article by Graves and Sheps in the American Journal
of Hypertension [126], the authors convey their opinion
on that: "Physicians do not measure BP well, and even if
they do, the usefulness of their BP measurements is signif-
icantly compromised by the white coat effect".
This might certainly be true, and I also agree that some-
thing should be done, however, extreme solutions like: "It
is clear from evidence trails that current practice of BP
measurement is inadequate. Thus, the question is not
whether physicians should or should not measure BP in
the hypertensive patients; rather, it is how are we to
replace the physician measurement with a higher quality
BP measurement", might be too long far fetched.
(Wondering, whether this speedy progress might, some
day, end up with doctors being disqualified to use a
stethoscope!)
The authors answer the hypothetical question and suggest
that "trained observers" or validated automated devices
should be used. They acknowledge, however, that
observer-dependent errors seen in "trained observers"
(commonly nurses) are similar in type and magnitude to
those seen in physicians [127].
The most recent AHA Scientific Statement [128] makes the
justifiable remark that: "...physician blood pressure meas-
urements should not be used exclusively in the routine
management of the hypertensive patient". It goes on to
say that: "With careful training even unpaid volunteers in
large population surveys can measure blood pressure
accurately [129]. However, even with the newer auto-
mated devices, the accuracy of the readings can be optimal
only if all observers are appropriately trained and
retrained and conscientious about using appropriate
technique".
Eligibility to become "Observer" is dependent on a
number of physical and cognitive competencies required
to perform, assess and report the blood pressure measure-
ment. The physical requirement includes vision, hearing
and eye/hand/ear coordination (see Additional file 5).
Furthermore, observers are supposed to undergo careful
evaluation as to their ability to assess "different types of
bias, general technique, and the interpretation of the
measurements including an understanding of the normal
variability of blood pressure by time of day, exercise, tim-
ing of antihypertensive medications, etc. The observers
should know how and when to communicate blood pres-
sure readings gathered at home or other settings to the
health care professional responsible for the care of the
patient and management of hypertension".
A comprehensive model of retraining of all observers is
suggested, whereby: "a central master trainer trains the site
master trainers, and they in turn train the observers at
each site. This model could be replicated within hospitals,
ambulatory care settings, and community agencies".
The AHA document gives insight in the area of home/self-
monitoring of blood pressure as a methodology that has
the potential to "improve both therapeutic compliance
and blood pressure control", according to two studies
from mid 80s [130,131].
Despite the benefits of home blood pressure measure-
ments – being more reliable than those recorded in the
clinic setting – the Working Group on Blood Pressure
Monitoring of the ESH neither recommend extensive use
of the model, nor empowers patients to take action on the
basis of the results [132]. Even without the empowerment
of measuring blood pressure themselves, patients take the
freedom to adjust their drug treatment or to quit it, with-
out necessarily taking into consideration the level of
blood pressure or the advice from a doctor. An estimated
50% of drugs prescribed for long term use are not taken
because of concerns for side effects and/or drug depend-
ency, a fact that powerfully impacts the overall compli-
ance figures [133].Current Controlled Trials in Cardiovascular Medicine 2005, 6:6 http://cvm.controlled-trials.com/content/6/1/6
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Furthermore, the main advantage of the home blood pres-
sure monitoring – accurate readings – is not a guarantee
of accurate reporting to the physician. This fact is high-
lighted in two studies employing measurement devices
with memory. Patients using them were supposed to care-
fully record their blood pressure and to report the results
to their physicians. More than half the subjects omitted or
fabricated readings [134,135]. Supposedly, only the other
halves of the patients were sufficiently well trained regard-
ing: "information about hypertension, procedure for self
monitoring, advice on equipment and its proper use, and
interpretation of protocol and data" [136].
ESC advocates the home blood pressure monitoring for
detecting white coat hypertension among patients with
persistently raised clinic blood pressure, however, it
emphasizes that a diagnosis requires confirmation with
ambulatory monitoring.
Conclusion
A widespread awareness seems to emerge as to the doubt-
ful clinical relevance of the most used investigation in
clinical practice – the blood pressure measurement.
As mentioned in this paper, a great number of factors are
contributing to the more than 100-year old method being
carefully scrutinized, primarily because of the biological,
random fluctuations of the blood pressure variable and
the white coat effect.
These two latter aspects, as well as many others (the
greater predictive value of the SBP, rather that that of the
DBP, the increasing cardiovascular risk parallel with rising
BP from values as low as 115/75 mmHg, the results of a
multitude of randomized clinical trials), have forged a big
quantum leap in our understanding of hypertension and
seem to bring about the need for radical change, a real par-
adigm shift in the way we see and deal with blood pres-
sure and with hypertension.
Sadly enough, the realization that the classically office-
based BP can, on no account, be relied upon for diagnosis
and treatment purposes, has generated a wave of mistrust
with the practicing physicians, commonly involved in the
management of patients with hypertension.
At closer scrutiny, however, most of the reproaches
directed toward physicians are exaggerated and many of
the "solutions" suggested extreme. Moreover, the peculiar
"physician behavior" might be a deliberate acting to
account for the uncertainties related to the much debated
BP range of 140/90 – 160/95 mmHg and for the failure of
the current health care systems to generalize implementa-
tion of ABPM in clinical practice, at least for all "first diag-
nosis" and treatment decision making.
The second part of this paper will attempt to elaborate on
these latter issues.
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